Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts

Rengaswamy Sankaranarayanan, Partha Basu, Prabhdeep Kaur, Rajesh Bhaskar, Gurinder Bir Singh, Phumzay Denzongpa, Rajesh K. Grover, Paul Sebastian, Tapan Saikia, Kunal Oswal, Rishav Kanodia, Amantia Dsouza, Ravi Mehrotra, Goura Kishor Rath, Viniita Jaggi, Sundram Kashyap, Ishu Kataria, Roopa Hariprasad, Peter Sasieni, Neerja BhatlaPreetha Rajaraman, Edward L. Trimble, Soumya Swaminathan, Arnie Purushotham

Research output: Contribution to journalReview articlepeer-review

Abstract

Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.

Original languageEnglish (US)
Pages (from-to)e637-e644
JournalThe Lancet Oncology
Volume20
Issue number11
DOIs
StatePublished - Nov 2019
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts'. Together they form a unique fingerprint.

Cite this